Search results for "Malignancy"

showing 10 items of 274 documents

Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project

2014

Background: Non-Hodgkin lymphoma (NHL), the most common hematologic malignancy, consists of numerous subtypes. The etiology of NHL is incompletely understood, and increasing evidence suggests that risk factors may vary by NHL subtype. However, small numbers of cases have made investigation of subtype-specific risks challenging. The International Lymphoma Epidemiology Consortium therefore undertook the NHL Subtypes Project, an international collaborative effort to investigate the etiologies of NHL subtypes. This article describes in detail the project rationale and design. Methods: We pooled individual-level data from 20 case-control studies (17 471 NHL cases, 23 096 controls) from North Ame…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyAdolescentChronic lymphocytic leukemiaFollicular lymphomaNon-Hodgkin lymphoma (NHL)ArticleLymphoplasmacytic LymphomaYoung AdultRisk Factorsimmune system diseaseshemic and lymphatic diseasesInternal medicineEpidemiology of cancerPrevalencemedicineHumansAgedAged 80 and overMycosis fungoidesbusiness.industryLymphoma Non-HodgkinAustraliaWaldenstrom macroglobulinemiaGeneral MedicineMiddle Agedmedicine.diseaseNon-Hodgkin's lymphomaEuropeOncologyCase-Control StudiesEpidemiologic Research DesignNorth AmericaImmunologyInternational Lymphoma Epidemiology Consortiumhematologic malignancyFemaleMantle cell lymphomabusinessJNCI Monographs
researchProduct

Quantitative DNA measurements in malignant and benign lesions of the upper aerodigestive tract.

1992

Thirty-six patients underwent biopsy of clinically suspicious lesions of the mucosa of the upper aerodigestive tract. The biopsy material was evaluated histologically and cytologic smears out of the same lesion underwent quantitative DNA analysis using a numerical index derived from the single cell DNA content. In 30 patients, histologically diagnosed squamous cell cancer was confirmed by DNA analysis with the malignancy grade correlating with the morphologic differentiation of the tumor. Six lesions were histologically benign: i.e. dysplasia (n = 3), hyperplasia (n = 2) and chronic inflammation (n = 1). DNA analysis confirmed the benign nature in 4 cases, but in 2 cases of dysplasia, a dia…

AdultMalePathologymedicine.medical_specialtyBiopsyMalignancyDigestive System NeoplasmsModels BiologicalLesionCytologyBiopsymedicineHumansAgedmedicine.diagnostic_testbusiness.industryHistologyDNAHyperplasiaMiddle Agedmedicine.diseaseFlow CytometryPrognosisUpper aerodigestive tractOtorhinolaryngologyDysplasiaCarcinoma Squamous CellFemalemedicine.symptombusinessORL; journal for oto-rhino-laryngology and its related specialties
researchProduct

Manifestations of the tongue in Neurofibromatosis type 1

2006

Objective:  The aim of this study is to analyse alterations of the tongue and the correlation between these lesions and different types of tumor. Subjects and methods:  A total of 258 cases (131 females, 127 males) of neurofibromatosis type 1 were screened between 1994 and 2004 in our Dermatology Department. All patients included in this study have NF1, as defined by the NIH Consensus Conference. Three cases of neurofibromas of the tongue in patients with neurofibromatosis type were reported. Results:  Our patients showed nodular lesions on the tongue, related to neurofibromas in two patients and plexiform neurofibroma in one patient, respectively. Clinical and hystopatological findings wer…

AdultMalePathologymedicine.medical_specialtyNeurofibromatosis 1Skin NeoplasmsBiopsyMalignancyDiagnosis DifferentialTonguePlexiform neurofibromaTongueBiopsyHumansMedicineNeoplasm InvasivenessNeurofibromatosisGeneral DentistryAgedNeurofibromamedicine.diagnostic_testbusiness.industryCafe-au-Lait SpotsPlexiform neurofibromaConsensus conferenceSoft tissuemedicine.diseaseTongue Neoplasmsmedicine.anatomical_structureOtorhinolaryngologyFemaleDifferential diagnosisbusinessNeurofibromatosis type 1Oral Diseases
researchProduct

Desmoplastic primitive nonneural granular cell tumor of the skin.

2014

Abstract Primitive nonneural granular cell tumor of the skin was first described by LeBoit et al in 1991 as "primitive polypoid granular cell tumor." Few cases have been reported to date, all being polypoid or deep well-delimited lesions and formed by large spindle or polygonal granular cells with moderate nuclear atypia and increased mitotic activity. This granular cell population does not have a Schwannian, myogenic, melanocytic, fibroblastic, histiocytic, or epithelial differentiation. We report a case that fully satisfies the criteria for primitive nonneural granular cell tumor of the skin and, in addition, shows an extensive desmoplastic stroma. This desmoplastic variant of primitive n…

AdultMalePathologymedicine.medical_specialtySkin NeoplasmsBiopsyPopulationDermatologyBiologyMalignancyPathology and Forensic MedicineDiagnosis DifferentialStromamedicineMalignant Granular Cell TumorHumansNuclear atypiaeducationMitosisHistiocyteSkinGranular cell tumoreducation.field_of_studyGeneral Medicinemedicine.diseaseGranular Cell TumorThe American Journal of dermatopathology
researchProduct

CD99 Immunoreactivity in Atypical Fibroxanthoma

2002

Atypical fibroxanthoma (AFX), a pleomorphic superficial cutaneous tumor of low-grade malignancy, shares many morphologic features with malignant melanoma (MM) and squamous cell carcinoma (SCC). Absence of S-100, keratin, and desmin immunoreactivity is the clue for this diagnosis. In a search for positive markers, we tested 26 cases of AFX with 2 antibodies: O13 (CD99) and protein gene product 9.5 (PGP9.5). We also included 10 cases of poorly differentiated SCC and 10 cases of MM in the study. In AFX, CD99 immunoreactivity was present in 19 cases (73%), whereas focal PGP9.5 immunoreactivity was found in only 9 cases (35%). None of the SCC cases showed CD99 immunostaining. No CD99 immunoreact…

AdultMalePathologymedicine.medical_specialtySkin NeoplasmsCD9912E7 AntigenMalignancyDiagnosis DifferentialAntigens CDBiomarkers TumorCarcinomamedicineHumansMelanomaAgedHistiocytoma Benign Fibrousbusiness.industryMelanomaAtypical fibroxanthomaGeneral MedicineMiddle Agedmedicine.diseaseEpidermoid carcinomaCarcinoma Squamous CellImmunohistochemistryFemaleThiolester HydrolasesbusinessCell Adhesion MoleculesUbiquitin ThiolesteraseImmunostainingAmerican Journal of Clinical Pathology
researchProduct

Soft tissue recurrent ameloblastomas also show some malignant features: a clinicopathological study of a 15-year database

2015

Background To investigate the clinicopathological features of six cases of soft tissue recurrent ameloblastoma and explore the role of increased aggressive biological behavior in the recurrences and treatment of this type of ameloblastomas. Material and Methods In this study, we retrospectively reviewed recurrent ameloblastomas during a 15-year period; six cases were diagnosed as soft tissue recurrent ameloblastoma. The clinical, radiographic, cytological and immunohistochemical records of these six cases were investigated and analyzed. Results All the six soft tissue recurrent ameloblastomas occurred after radical bone resection, and were located in the adjacent soft tissues around the ost…

AdultMalePathologymedicine.medical_specialtySoft Tissue NeoplasmTime FactorsDatabases FactualSoft Tissue NeoplasmsOdontologíaMalignancyAtypical hyperplasiaMalignant transformationAmeloblastomaAtypiaMedicineHumansAmeloblastomaGeneral DentistryPathologicalAgedRetrospective Studiesbusiness.industryResearchSoft tissueMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryFemaleOral SurgeryNeoplasm Recurrence Localbusiness
researchProduct

P53 and bcl-2 immunoexpression in patients with oral lichen planus a nd oral squamous cell carcinoma

2012

Objective: The aim of this study was to determine by immunohistochemistry the presence and significance of p53 and bcl-2 proteins in oral lichen planus (OLP) and oral squamous cell carcinoma (OSCC). Study Design: We used 21 cases diagnosed as OLP 16 diagnosed as OSCC and four normal gingival biopsies taken from healthy patients were used as controls. Slides were processed for immunohistochemistry using anti-p53 and anti-bcl-2 monoclonal antibodies. Results: We found p53 immunoexpression in 71.4� OLP cases and 6� .7� OSCC cases, with no immunoexpres: We found p53 immunoexpression in 71.4� OLP cases and 6� .7� OSCC cases, with no immunoexpresWe found p53 immunoexpression in 71.4� OLP cases an…

AdultMalePathologymedicine.medical_specialtymedicine.drug_classMonoclonal antibodyMalignancyYoung Adultstomatognathic systemmedicineCarcinomaHumansIn patientBasal cellGeneral DentistryAgedMouth neoplasmOral Medicine and Pathologybusiness.industryMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]stomatognathic diseasesProto-Oncogene Proteins c-bcl-2OtorhinolaryngologyUNESCO::CIENCIAS MÉDICASCarcinoma Squamous CellImmunohistochemistryResearch-ArticleFemaleMouth NeoplasmsSurgeryOral lichen planusTumor Suppressor Protein p53businessLichen Planus Oral
researchProduct

Long-term Evolution of Hepatocellular Adenomas at MRI Follow-up.

2020

Background Hepatocellular adenomas (HCAs) are rare benign liver tumors. Guidelines recommend continued surveillance of patients diagnosed with HCAs, but these guidelines are mainly based on small studies or expert opinion. Purpose To analyze the long-term evolution of HCAs, including solitary and multiple lesions, and to identify predictive features of progression with MRI. Materials and Methods In a retrospective study, patients diagnosed with pathologically proven solitary or multiple HCAs between January 2004 and December 2015 were included; β-catenin-mutated HCAs and HCAs with foci of malignancy were considered to be at risk for progression. MRI examinations were analyzed, and tumor evo…

AdultMalePediatricsmedicine.medical_specialtyCarcinoma HepatocellularAdenomahepatocellular adenomaMEDLINEDiseaseliverMalignancyGastroenterology030218 nuclear medicine & medical imagingAdenoma Liver Cell03 medical and health sciencessymbols.namesakeText mining0302 clinical medicineMcNemar's testInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingFisher's exact testResponse Evaluation Criteria in Solid TumorsRetrospective Studiesbusiness.industryLiver NeoplasmsRetrospective cohort studymedicine.diseaseMagnetic Resonance ImagingTerm (time)Response Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesissymbolsDisease ProgressionFemalebusinessProgressive diseaseMRIFollow-Up StudiesRadiology
researchProduct

Second Malignancies Following Childhood Cancer Treatment in Germany From 1980 to 2014.

2018

BACKGROUND Because of improvements in cancer treatment, more than 80% of all children with cancer now survive at least five years from the time of diagnosis. As a result, late sequelae of cancer and its treatment have become more common, particularly second malignancies. We studied the current incidence of second malignancies among childhood cancer survivors in Germany. METHODS This study is based on the cohort of the German Childhood Cancer Registry (Deutsches Kinderkrebsregister, DKKR). Persons given the diagnosis of a first malignancy at any time in the years 1980-2014 who were no more than 14 years old at the time of diagnosis and survived at least six months thereafter were included in…

AdultMalePediatricsmedicine.medical_specialtyPopulationMalignancy03 medical and health sciencesYoung Adult0302 clinical medicineCancer SurvivorsRisk FactorsGermanymedicineHumansCumulative incidence030212 general & internal medicineRegistrieseducationChildProportional Hazards Modelseducation.field_of_studyChildhood Cancer Registrybusiness.industryIncidence (epidemiology)IncidenceHazard ratioCancerNeoplasms Second PrimaryGeneral MedicineMiddle Agedmedicine.diseaseAdult Survivors of Child Adverse Events030220 oncology & carcinogenesisCohortFemaleOriginal ArticlebusinessDeutsches Arzteblatt international
researchProduct

Omalizumab and the risk of malignancy: results from a pooled analysis.

2011

Background Since initial registration, the omalizumab clinical trial database has expanded considerably, with a doubling of patients exposed in the clinical trial environment. Previous pooled data (2003) from phase I to III studies of omalizumab showed a numeric imbalance in malignancies arising in omalizumab recipients (0.5%) compared with control subjects (0.2%). The previous analysis was based on limited available data, warranting further investigation. Objective We sought to examine the incidence of malignancy using comprehensive pooled data from clinical trials of omalizumab-treated patients. Methods This pooled analysis included data from 67 phase I to IV clinical trials. The prespeci…

AdultMaleRiskmedicine.medical_specialtyAdolescentImmunologyOmalizumabOmalizumabRate ratioMalignancyAntibodies Monoclonal HumanizedYoung AdultInternal medicineNeoplasmsImmunology and AllergyMedicineHumansAnti-Asthmatic AgentsYoung adultAdverse effectChildAsthmaAgedAged 80 and overbusiness.industryIncidence (epidemiology)IncidenceAntibodies MonoclonalMiddle Agedmedicine.diseaseSurgeryAntibodies Anti-IdiotypicClinical trialChild PreschoolFemalebusinessmedicine.drugThe Journal of allergy and clinical immunology
researchProduct